Table 3. Univariate and multivariate analysis of survival stratified by pathologic type.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (years) | 0.251 | ||||
| <65 | 1.00 (reference) | ||||
| ≥65 | 0.76 (0.48–1.20) | ||||
| Gender | 0.922 | ||||
| Male | 1.00 (reference) | ||||
| Female | 1.02 (0.60–1.75) | ||||
| BMI (kg/m2) | 0.858 | ||||
| <22.0 | 1.00 (reference) | ||||
| ≥22.0 | 0.95 (0.61–1.51) | ||||
| Baseline CRP (mg/L) | <0.001 | <0.001 | |||
| <10 | 1.00 (reference) | 1.00 (reference) | |||
| ≥10 | 2.71 (1.71–4.30) | 2.45 (1.53–6.39) | |||
| Histology | 0.137 | ||||
| Adenocarcinoma | 1.00 (reference) | ||||
| Non-adenocarcinoma | 1.40 (0.90–2.18) | ||||
| PD-L1 expression | 0.157 | ||||
| <50% | 1.00 (reference) | ||||
| ≥50% | 0.54 (0.23–1.26) | ||||
| ECOG PS | 0.004 | 0.002 | |||
| 0–1 | 1.00 (reference) | 1.00 (reference) | |||
| ≥2 | 4.34 (2.17–8.70) | 3.12 (1.52–6.39) | |||
| irAEs incidence | 0.236 | ||||
| No | 1.00 (reference) | ||||
| Yes | 0.94 (0.60–1.48) | ||||
| Clinical stage | 0.181 | ||||
| III | 1.00 (reference) | ||||
| IV | 1.96 (1.01–3.80) | ||||
| EGFR | 0.823 | ||||
| Wild type | 1.00 (reference) | ||||
| Mutant | 0.52 (0.19–1.46) | ||||
HR, hazard ratio; CI, confidence interval; BMI, body mass index; CRP, C-reactive protein; PD-L1, programmed cell death ligand 1; ECOG PS, Eastern Cooperative Oncology Group performance status; irAEs, immune-related adverse events; EGFR, epidermal growth factor receptor.